» Articles » PMID: 25356594

Biocompatible Anionic Polymeric Microspheres As Priming Delivery System for Effetive HIV/AIDS Tat-based Vaccines

Abstract

Here we describe a prime-boost regimen of vaccination in Macaca fascicularis that combines priming with novel anionic microspheres designed to deliver the biologically active HIV-1 Tat protein and boosting with Tat in Alum. This regimen of immunization modulated the IgG subclass profile and elicited a balanced Th1-Th2 type of humoral and cellular responses. Remarkably, following intravenous challenge with SHIV89.6Pcy243, vaccinees significantly blunted acute viremia, as compared to control monkeys, and this control was associated with significantly lower CD4+ T cell depletion rate during the acute phase of infection and higher ability to resume the CD4+ T cell counts in the post-acute and chronic phases of infection. The long lasting control of viremia was associated with the persistence of high titers anti-Tat antibodies whose profile clearly distinguished vaccinees in controllers and viremics. Controllers, as opposed to vaccinated and viremic cynos, exhibited significantly higher pre-challenge antibody responses to peptides spanning the glutamine-rich and the RGD-integrin-binding regions of Tat. Finally, among vaccinees, titers of anti-Tat IgG1, IgG3 and IgG4 subclasses had a significant association with control of viremia in the acute and post-acute phases of infection. Altogether these findings indicate that the Tat/H1D/Alum regimen of immunization holds promise for next generation vaccines with Tat protein or other proteins for which maintenance of the native conformation and activity are critical for optimal immunogenicity. Our results also provide novel information on the role of anti-Tat responses in the prevention of HIV pathogenesis and for the design of new vaccine candidates.

Citing Articles

Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease.

Cafaro A, Tripiciano A, Picconi O, Sgadari C, Moretti S, Butto S Vaccines (Basel). 2019; 7(3).

PMID: 31454973 PMC: 6789840. DOI: 10.3390/vaccines7030099.

References
1.
Turbant S, Martinon F, Moine G, Le Grand R, Leonetti M . Cynomolgus macaques immunized with two HIV-1 Tat stabilized proteins raise strong and long-lasting immune responses with a pattern of Th1/Th2 response differing from that in mice. Vaccine. 2009; 27(39):5349-56. DOI: 10.1016/j.vaccine.2009.06.083. View

2.
van de Weert M, Hennink W, Jiskoot W . Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res. 2001; 17(10):1159-67. DOI: 10.1023/a:1026498209874. View

3.
Caputo A, Brocca-Cofano E, Castaldello A, De Michele R, Altavilla G, Marchisio M . Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application. Vaccine. 2004; 22(21-22):2910-24. DOI: 10.1016/j.vaccine.2003.12.025. View

4.
Tomaras G, Haynes B . HIV-1-specific antibody responses during acute and chronic HIV-1 infection. Curr Opin HIV AIDS. 2010; 4(5):373-9. PMC: 3133462. DOI: 10.1097/COH.0b013e32832f00c0. View

5.
Bachler B, Humbert M, Palikuqi B, Siddappa N, Lakhashe S, Rasmussen R . Novel biopanning strategy to identify epitopes associated with vaccine protection. J Virol. 2013; 87(8):4403-16. PMC: 3624354. DOI: 10.1128/JVI.02888-12. View